Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

46.060
-1.880-3.92%
Volume:4.82M
Turnover:222.96M
Market Cap:305.70B
PE:33.45
High:47.940
Open:47.940
Low:45.740
Close:47.940
52wk High:94.869
52wk Low:45.660
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:0.51
T/O Rate:1.87%
Dividend:0.23
Dividend Rate:0.51%
EPS(LYR):1.377
ROE:12.46%
ROA:7.02%
PB:4.06
PE(LYR):33.45
PS:8.36

Loading ...

Movement Alert|HENGRUI PHARMA Falls 3.05% in Regular Trading, Mid-Year Earnings Under Pressure Amid Broad Pharma Sector Weakness

Market Focus
·
Yesterday

Hengrui Pharma's Interim Report Falls Flat: Legacy Blockbusters Fade as Revenue Posts First Half-Year Decline in Four Years

Deep News
·
Aug 27

Movement Alert|HENGRUI PHARMA Rises 3.04% in Regular Trading, GIC Private Limited Consecutively Increases Stake to 17.19%

Market Focus
·
Aug 27

Singapore Sovereign Fund Boosts Stake in Chinese Drugmaker with HK$185 Million Share Purchase

Deep News
·
Aug 27

JPMorgan Chase & Co.'S Short Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Increases to 3.72% on August 21 from 2.57% - HKEX

THOMSON REUTERS
·
Aug 26

Singapore's GIC Boosts Stake in Hengrui Pharma With HK$185 Million Share Purchase

Stock News
·
Aug 25

HENGRUI PHARMA: GIC Private Limited Acquires Shares, Long Position Rises to 15.7%

HK Disclosure
·
Aug 25

Chinese Drug Regulator Accepts Hengrui Pharma's Drug Marketing Application for HRG2010 Capsules

MT Newswires Live
·
Aug 25

HENGRUI PHARMA's HRG2010 Capsule Marketing Application Accepted by NMPA

Stock News
·
Aug 24

Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$82.18 From HK$87.49, Keeps at Buy

MT Newswires Live
·
Aug 24

Hengrui Pharma's Half-Year Report: Heavy Spending Fails to Drive Growth as Former Sector Leader Struggles with Revenue Without Profit Expansion

Deep News
·
Aug 24

Movement Alert|HENGRUI PHARMA Falls 3.03% in Regular Trading, BOCOM International Cuts Target Price Citing Continued Pressure on Legacy Products

Market Focus
·
Aug 24

Hengrui Pharma's Growth Architecture Shifts: Second Growth Engine Accelerates as Global Valuation Framework Expands

Stock News
·
Aug 23

Hengrui Pharma Gets Nod to Trial SHR-8203 Injection

MT Newswires Live
·
Aug 21

Hengrui Pharma Unit Gets China Nod for Lupus Drug Trial

MT Newswires Live
·
Aug 21

Movement Alert|HENGRUI PHARMA Declines 3.18% in Regular Trading, Extending Sell-Off on Weak H1 Earnings Quality

Market Focus
·
Aug 21

Hengrui Pharmaceuticals Unit Gets China Marketing Nod for Paroxysmal Nocturnal Hemoglobinuria Drug

MT Newswires Live
·
Aug 20

Jiangsu Hengrui Pharmaceuticals- Nmpa Notice Approving Developed Class 1 Innovative Drug Licancopan Fumarate (Hrs-5965) Capsules for Marketing

THOMSON REUTERS
·
Aug 20

HENGRUI PHARMA (01276) Gets Clinical Trial Approval for SHR-7012 Injection Targeting Cutaneous Lupus Erythematosus

Stock News
·
Aug 20

Jiangsu Hengrui Hong Kong Shares Hit Record Low on Quarterly Profit Miss

Reuters
·
Aug 20